Last reviewed · How we verify
NCT00066807: PERCHE
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
Phase 3 trial testing chemotherapy in Breast Cancer in 29 participants. Terminated before completion.
1 December 2006
Quick facts
| Lead sponsor | ETOP IBCSG Partners Foundation |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 1 August 2003 |
| Primary completion | 1 December 2006 |
| Estimated completion | 1 December 2006 |
| Sites | 6 locations across Hungary, Italy, Switzerland |
Drugs / interventions tested
- chemotherapy
- exemestane (exemestane) — full drug profile →
- tamoxifen — full drug profile →
- triptorelin (triptorelin) — full drug profile →
- oophorectomy
- ovarian irradiation
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
ETOP IBCSG Partners Foundation
Who can join
Adults 18 to 65, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Disease-free Survival
Time frame: For first time at a median follow up approximately 5 years
Sponsor's own description
The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or exemestane for five years. The use of chemotherapy was determined by randomization. The method of ovarian function suppression (GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice of tamoxifen or exemestane were determined by the investigator or by randomization in the IBCSG 25-02 TEXT trial \[recommended option\]. The trial was terminated early due to poor accrual.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
Tao JJ, Visvanathan K, Wolff AC. · · 2015 · cited 151× · PMID 26299406 · DOI 10.1016/j.breast.2015.07.035 -
Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M, Mora AD, Ballatore Z, Berardi R. · · 2018 · cited 40× · PMID 29719441 · DOI 10.3747/co.25.3735
Verify or expand the search:
- PubMed search for NCT00066807
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of chemotherapy
Trials testing the same drug.
- NCT07035392 — Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC · Phase 2 · not yet recruiting
- NCT06599827 — Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC · Phase 2 · not yet recruiting
- NCT07437898 — Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study · Phase 2 · recruiting
- NCT06306560 — A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. · Phase 2 · not yet recruiting
- NCT06121505 — Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced · Phase 2 · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other ETOP IBCSG Partners Foundation trials
Trials by the same sponsor.
- NCT05718297 — Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer · Phase 2 · withdrawn
- NCT05896566 — A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients Wi · Phase 2 · completed
- NCT05601973 — Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progressio · Phase 2 · active not recruiting
- NCT04908956 — Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) · Phase 2 · terminated
- NCT04245085 — ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00066807 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ETOP IBCSG Partners Foundation
- Last refreshed: 26 September 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00066807.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing